Management of type 2 diabetes (T2D) in primary care is challenging because of the complexity of T2D, time constraints, guidance overload, evolving treatments and the current coronavirus disease pandemic.

Glucagon-like peptide 1 receptor agonists (GLP1 RAs) are an effective treatment option in primary care for people with T2D, achieving HbA1c reductions, weight loss and potential cardiovascular benefit, as monotherapy or as add-on to other glucose-lowering therapies.

This review provides a summary of clinical and real-world evidence along with practical guidance, with the aim of aiding primary care clinicians in the initiation and monitoring of GLP-1 RAs to ensure desired outcomes.

Furthermore, a benefit/risk tool has been developed to support primary care clinicians in selecting individuals who are most likely to benefit from GLP-1 RA therapies, in addition to indicating clinical situations where caution is needed.